Targeting a systolic blood pressure (BP) of less than 120 mm Hg lowered the incidence of major cardiovascular events compared with a target of less than 140 mm Hg among participants with elevated BP and a previous ischemic stroke or transient ischemic attack, according to a multicenter, open-label, randomized trial conducted at 30 sites in Brazil. In the trial, 4368 participants (mean age, 63.9 years; 47.9% women) were assigned to intensive treatment (2172 participants) or standard treatment (2196 participants); during follow-up excluding the first 3 months, mean systolic BP was 122.0 mm Hg in the intensive group versus 135.2 mm Hg in the standard group, a between-group difference of 13.1 mm Hg. Over a median follow-up of 3.9 years, a primary-outcome event—a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina or heart failure—occurred in 236 participants (10.9%; 3.25 events per 100 person-years) with intensive treatment and in 297 (13.5%; 4.11 events per 100 person-years) with standard treatment (hazard ratio, 0.79). The composite renal outcome (sustained reduction of ≥50% in the estimated glomerular filtration rate or progression to end-stage renal disease) was more common with intensive treatment, while the overall incidence of serious adverse events was similar in the two groups, suggesting that intensive BP control may offer cardiovascular benefit in this population despite the renal signal. Source: https://www.nejm.org/
In patients with type 2 diabetes (T2D) and high cardiovascular risk, targeting a systolic blood…
Among older adults with at least two chronic conditions but no known cardiovascular disease, discontinuing…
Two randomized, placebo-controlled trials of targeted therapies—ziltivekimab, a monoclonal antibody neutralizing interleukin-6, and pelacarsen, an…
Among US Medicare beneficiaries, colder ambient temperatures were associated with increased heart failure hospitalizations while…
In the 10-year extended follow-up of the DECISION-CTO trial, an initial strategy of percutaneous coronary…
In a randomized, open-label, noninferiority trial, a coronary computed tomographic angiography (CCTA)–guided percutaneous coronary intervention…
This website uses cookies.